SCHEMBL3673073

SCHEMBL3673073

CCSCCNC(=O)c1ccc(N2CCN(C(=O)c3cc(F)c(F)c(F)c3F)CC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
NPC1 O15118 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40
PKM P14618 2/20 0.39
P2RY12 Q9H244 1/20 0.39
KCNQ3 O43525 2/20 0.38
KCNQ2 O43526 2/20 0.38
FOLH1 Q04609 1/20 0.38
USP30 Q70CQ3 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668624 0.88 SCD (0.53) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3675218 0.88 SCD (0.52) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3673527 0.87 SCD (0.51) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3668611 0.86 SCD (0.68) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3676508 0.85 SCD (0.51) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3674275 0.84 SCD (0.49) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3671151 0.84 SCD (0.51) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3673062 0.84 LMNA (0.56) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3677075 0.84 SCD (0.49) SCDSMN1; SMN2ALDH1A1LMNANPC1
SCHEMBL3675782 0.83 SCD (0.53) SCDSMN1; SMN2ALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT SCD 10/4885SMN1; SMN2 112/4885ALDH1A1 1127/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 SCD 1186/4885SMN1; SMN2 123/4885ALDH1A1 3898/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT SCD 10/4885SMN1; SMN2 112/4885ALDH1A1 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.